CA2494489A1 - Method of making microcapsules utilizing a fluid ejector - Google Patents
Method of making microcapsules utilizing a fluid ejector Download PDFInfo
- Publication number
- CA2494489A1 CA2494489A1 CA002494489A CA2494489A CA2494489A1 CA 2494489 A1 CA2494489 A1 CA 2494489A1 CA 002494489 A CA002494489 A CA 002494489A CA 2494489 A CA2494489 A CA 2494489A CA 2494489 A1 CA2494489 A1 CA 2494489A1
- Authority
- CA
- Canada
- Prior art keywords
- fluid
- accordance
- drop
- ejecting
- microcapsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 264
- 239000003094 microcapsule Substances 0.000 title claims abstract description 100
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 159
- 239000008358 core component Substances 0.000 claims abstract description 37
- 230000003213 activating effect Effects 0.000 claims abstract description 21
- 230000004913 activation Effects 0.000 claims abstract description 6
- 238000009826 distribution Methods 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- 239000000178 monomer Substances 0.000 claims description 18
- 229920001661 Chitosan Polymers 0.000 claims description 17
- 239000000306 component Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 12
- 102000001554 Hemoglobins Human genes 0.000 claims description 11
- 108010054147 Hemoglobins Proteins 0.000 claims description 11
- 239000000376 reactant Substances 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 10
- 229940072056 alginate Drugs 0.000 claims description 9
- 229920000615 alginic acid Polymers 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- -1 alkali metal alginate Chemical class 0.000 claims description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 239000003595 mist Substances 0.000 claims description 5
- 229920000447 polyanionic polymer Polymers 0.000 claims description 5
- 239000010409 thin film Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 239000012867 bioactive agent Substances 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000010278 pulse charging Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 27
- 239000003814 drug Substances 0.000 description 23
- 239000011162 core material Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 18
- 239000011257 shell material Substances 0.000 description 17
- 239000001110 calcium chloride Substances 0.000 description 10
- 229910001628 calcium chloride Inorganic materials 0.000 description 10
- 235000011148 calcium chloride Nutrition 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 8
- 230000000975 bioactive effect Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 235000010413 sodium alginate Nutrition 0.000 description 6
- 239000000661 sodium alginate Substances 0.000 description 6
- 229940005550 sodium alginate Drugs 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000008827 biological function Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000005354 coacervation Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000010406 interfacial reaction Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F21—LIGHTING
- F21S—NON-PORTABLE LIGHTING DEVICES; SYSTEMS THEREOF; VEHICLE LIGHTING DEVICES SPECIALLY ADAPTED FOR VEHICLE EXTERIORS
- F21S9/00—Lighting devices with a built-in power supply; Systems employing lighting devices with a built-in power supply
- F21S9/02—Lighting devices with a built-in power supply; Systems employing lighting devices with a built-in power supply the power supply being a battery or accumulator
- F21S9/03—Lighting devices with a built-in power supply; Systems employing lighting devices with a built-in power supply the power supply being a battery or accumulator rechargeable by exposure to light
- F21S9/037—Lighting devices with a built-in power supply; Systems employing lighting devices with a built-in power supply the power supply being a battery or accumulator rechargeable by exposure to light the solar unit and the lighting unit being located within or on the same housing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/10—Complex coacervation, i.e. interaction of oppositely charged particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
- B01J13/16—Interfacial polymerisation
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F21—LIGHTING
- F21V—FUNCTIONAL FEATURES OR DETAILS OF LIGHTING DEVICES OR SYSTEMS THEREOF; STRUCTURAL COMBINATIONS OF LIGHTING DEVICES WITH OTHER ARTICLES, NOT OTHERWISE PROVIDED FOR
- F21V25/00—Safety devices structurally associated with lighting devices
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F21—LIGHTING
- F21W—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES F21K, F21L, F21S and F21V, RELATING TO USES OR APPLICATIONS OF LIGHTING DEVICES OR SYSTEMS
- F21W2111/00—Use or application of lighting devices or systems for signalling, marking or indicating, not provided for in codes F21W2102/00 – F21W2107/00
- F21W2111/02—Use or application of lighting devices or systems for signalling, marking or indicating, not provided for in codes F21W2102/00 – F21W2107/00 for roads, paths or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Sustainable Development (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Abstract
A method of making microcapsules including activating a fluid ejector at a frequency greater than 10 kilohertz where each activation of the fluid ejector generates essentially a drop, and the fluid ejector is fluidically coupled to a first fluid including a core component. The method further includes ejecting the drop of the first fluid into a second fluid, the drop having a volume. In addition, the method includes generating a microcapsule, that includes the core component, in the second fluid for each drop of the first fluid ejected.
Description
METHOD OF MAKING MICROCAPSULES UTILIZING A FLUID EJECTOR
BACKGROUND
Description of the Art [0001] Micro-encapsulation techniques are increasingly being utilized in such diverse areas as drug delivery systems, cosmetics, agricultural, chemical, and food industries to enhance the effectiveness of a particular component at the lowest possible cost. Generally, microcapsule drug delivery systems are intended for oral, inhalation parenteral, ocular, or topical use. The release of orally administered medications may occur in the oral cavity such as for buccal or sublingual administration, or may occur in the gastrointestinal tract after the oral dosage form is swallowed. There are, for example, capsules and tablets that contain microcapsules to release the drug in the stomach, enteric-coated formulations that release the medication in the intestinal tract of the patient, and controlled release dosage capsules that release the drug in both the stomach and the intestines. Some microcapsules release drug in the lower intestinal tract including the colon. The profile and kinetic pattern governing the release rate of an entrapped active component from a microcapsule depends on the nature and morphology of the shell material encapsulating the active component; and formulation ingredients within the core and the shell material. Further, many individuals suffer from chronic health problems that require the regular administration of medicaments. Diseases such as diabetes, allergies, epilepsy, heart problems, AIDS, and even cancers require the regular delivery of precise doses of medicaments if patients are to survive over long periods of time.
BACKGROUND
Description of the Art [0001] Micro-encapsulation techniques are increasingly being utilized in such diverse areas as drug delivery systems, cosmetics, agricultural, chemical, and food industries to enhance the effectiveness of a particular component at the lowest possible cost. Generally, microcapsule drug delivery systems are intended for oral, inhalation parenteral, ocular, or topical use. The release of orally administered medications may occur in the oral cavity such as for buccal or sublingual administration, or may occur in the gastrointestinal tract after the oral dosage form is swallowed. There are, for example, capsules and tablets that contain microcapsules to release the drug in the stomach, enteric-coated formulations that release the medication in the intestinal tract of the patient, and controlled release dosage capsules that release the drug in both the stomach and the intestines. Some microcapsules release drug in the lower intestinal tract including the colon. The profile and kinetic pattern governing the release rate of an entrapped active component from a microcapsule depends on the nature and morphology of the shell material encapsulating the active component; and formulation ingredients within the core and the shell material. Further, many individuals suffer from chronic health problems that require the regular administration of medicaments. Diseases such as diabetes, allergies, epilepsy, heart problems, AIDS, and even cancers require the regular delivery of precise doses of medicaments if patients are to survive over long periods of time.
[0002] Unfortunately, conventional oral dosage forms suffer from a number of disadvantages. Typically, to effectively handle and dispense small doses a considerable amount of adjuvant material must be added in order that the final dosage form is of a manageable size. Thus, typical methods for manufacturing include the mixing of the pure drug with various other substances commonly referred to as excipients or diluents that are therapeutically inert and acceptable by regulatory bodies, such as the Federal Drug Administration (FDA).
Many if not most micro-encapsulation techniques generate a broad distribution of microcapsule sizes. The broad distribution in microcapsule size makes it more difficult to accurately dispense an optimal drug dosage. In addition, it produces greater variability in dissolution rates and, thus, decreases the control over the absorption rate of the drug in the body. In addition, there is an increasing need to control the drug absorption process to sustain adequate and effective drug levels over a prolonged time period.
Many if not most micro-encapsulation techniques generate a broad distribution of microcapsule sizes. The broad distribution in microcapsule size makes it more difficult to accurately dispense an optimal drug dosage. In addition, it produces greater variability in dissolution rates and, thus, decreases the control over the absorption rate of the drug in the body. In addition, there is an increasing need to control the drug absorption process to sustain adequate and effective drug levels over a prolonged time period.
[0003] The availability of useful drug delivery systems that provide an optimal drug dosage to be delivered to a particular site in the body by means of microcapsule dosage forms is very limited. The ability to control and extend the release of an active component from a microcapsule without adversely modifying the structure or normal biological function of the active component in the body after administration and absorption is also extremely limited today. If these problems persist, many new and potentially life saving beneficial drugs will either be impractical or have limited effectiveness in the dosage forms currently available.
As the demands for more efficient and lower cost drugs continues to grow, the demand to develop systems or drug carriers capable of delivering the active molecules specifically to the intended target organ, while increasing the therapeutic efficacy will continue to increase as well.
BRIEF DESCRIPTION OF THE DRAWINGS
As the demands for more efficient and lower cost drugs continues to grow, the demand to develop systems or drug carriers capable of delivering the active molecules specifically to the intended target organ, while increasing the therapeutic efficacy will continue to increase as well.
BRIEF DESCRIPTION OF THE DRAWINGS
[0004] Fig. 1 a is a cross-sectional view of a fluid ejection device according to an embodiment of the present invention.
[0005] Fig. 1 b is a graph illustrating a normalized drop-volume distribution of a conventional fluid ejector.
(0006) Fig. 1c is a graph illustrating a normalized drop-volume distribution of a fluid ejection device according to an embodiment of the present invention.
(0007] Fig. 2a is a cross-sectional view of a microcapsule according to an embodiment of the present invention.
[0008] Fig. 2b is a cross-sectional view of a microcapsule according to an alternate embodiment of the present invention.
[0009] Fig. 3 is a flow diagram of a method of manufacturing microcapsules according to an embodiment of the present invention.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
DESCRIPTION OF THE PREFERRED EMBODIMENTS
(0010] The present invention advantageously utilizes a fluid ejection device to eject drops of a precise volume of a fluid, that includes a core material component, into a second fluid and generates a microcapsule in the second fluid, with the core material component encapsulated within the microcapsule. The present invention may utilize a wide variety of fluid ejection devices including both continuous and drop on demand types of fluid ejection devices. For example, thermally activated fluid ejection devices, piezoelectric, and acoustic activation as well as others may be utilized in the present invention. The present invent'ron provides both for smaller drop volumes as well as greater control over repeatability of drop volume with its corresponding narrower distribution of drop volumes than typical microcapsule forming techniques.
[0011] For purposes of this description and the present invention, the term core material component may include, semiconductor, metal, bioactive, inorganic, organic, and polymeric materials having an advantageous property or utility encapsulated as nanometer or micrometer sized capsules or particulates. The term "bioactive" as used with fluid, composition, substance, or agent, may be a composition that affects a biological function of a living organism including plants, invertebrates or vertebrates directly or as a result of a metabolic or chemical modification associated with the organism or its vicinal environment. For example, a bioactive fluid may include any pharmaceutical substance, such as a drug, which may be given to alter a physiological condition of an organism, such as a disease.
A bioactive fluid is meant to include any type of drug, medication, medicament, vitamin, nutritional supplement, or other compound that is designed to affect a biological function of a vertebrate. The term bioactive is also meant to include any substance including, but not limited to, insecticides, pesticides, or herbicides designed to affect a biological function.
A bioactive fluid is meant to include any type of drug, medication, medicament, vitamin, nutritional supplement, or other compound that is designed to affect a biological function of a vertebrate. The term bioactive is also meant to include any substance including, but not limited to, insecticides, pesticides, or herbicides designed to affect a biological function.
(0012] An embodiment of fluid ejection device 102 that may be utilized to prepare microcapsules according to the present invention is illustrated, in a cross-sectional view, in Fig. 1a. In this embodiment, fluid reservoir 118, in a body portion of fluid ejection device 102, contains a first fluid that includes a core material to be encapsulated in a second fluid. Fluid reservoir 118 is fluidically coupled to a substrate 120 via fluid inlet passage 124. Depending on the particular fluid ejection device utilized generally substrate 120 is attached to device body 122. In alternate embodiments, substrate 120 may include integrated circuitry and may be mounted to what is commonly referred to as a chip carrier (not shown), which is attached to device body 122. The substrate 120 generally contains an energy-generating element or fluid ejector 126 that generates the force utilized to eject essentially a drop of fluid held in chamber 132. Fluid or drop ejector 126 creates a discrete number of drops of a substantially fixed size or volume. Two widely used energy generating elements are thermal resistors and piezoelectric elements. The former rapidly heats a component in the fluid above its boiling point causing vaporization of the fluid component resulting in ejection of a drop of the fluid. While the latter utilizes a voltage pulse to generate a compressive force on the fluid resulting in ejection of a drop of the fluid. For more information on various transducers utilized 5 in drop-on-demand fluid ejection cartridges see Stephen F. Pond, Ph.D., Inkiet Technoloav and Product Develoament Strategies, ch 4 (Torrey Pines Research, 2000); and more particularly for thermal inkjet device technology see J.
Stephen Aden et al., The Third-Generation HP Thermal InkJet Printhead, Hewlett-Packard Journal, vol. 45, no. 1, pg. 41-45, February 1994.
Stephen Aden et al., The Third-Generation HP Thermal InkJet Printhead, Hewlett-Packard Journal, vol. 45, no. 1, pg. 41-45, February 1994.
[0013] Substrate 120, chamber layer 130, nozzle layer 140, nozzles 142, and a flexible circuit (not shown) form what is generally referred to as ejector head 104. Chamber layer 130 forms the side walls of chamber 132 and substrate 120 and nozzle layer 140 form the bottom and top of chamber 132 respectively, where the substrate is considered the bottom of the chamber. In this embodiment, fluid ejection device 102 has a nozzle density of 300 nozzles per inch; however, in alternate embodiments, nozzle densities may range from a single nozzle up to over a 1000 per inch. In addition, in this embodiment, nozzle layer 140 contains one nozzle per fluid ejector through which fluid is ejected; however, in alternate embodiments, each fluid ejector may utilize multiple nozzles through which fluid is ejected. Each activation of a fluid ejector results in the ejection of a precise quantity of fluid in the form of essentially a fluid drop with the drop ejected substantially along fluid ejection axis 148. Each fluid drop may include primary drop 146 as well as possible secondary drops 144. Both the generation and size of the secondary drops depends on various parameters such as the firing frequency of fluid ejector 126, the surface tension of the fluid being ejected, the size and shape of nozzle 142, and the size, shape, and location of fluid ejector 126 to nozzle 142. The number of times the fluid ejector is activated, in this embodiment, controls the number of drops ejected. In this embodiment, fluid ejection device 102 operates at a frequency of greater than about 10 kilohertz for each fluid ejector or energy generating element. In alternate embodiments, fluid ejection device 102 having active circuitry integrated on substrate 120 may operate at frequencies greater than 20 kilohertz. Fluid ejection device 102 precisely controls in a discretely drop-by-drop manner the ejection of a fluid held in chamber 132.
For more information on drop formation see, for example, Jaime H. Bohorquez et al., Laser-Comparable Inkiet Text Printing, Hewlett-Packard Journal, vol. 45, no.
1, pg.
9-17, February 1994; or William A. Buskirk et al., Development of a High Resolution Thermal Inkiet Printhead, Hewlett-Packard Journal, vol. 39, no. 5, pg.
55-61, October 1988.
For more information on drop formation see, for example, Jaime H. Bohorquez et al., Laser-Comparable Inkiet Text Printing, Hewlett-Packard Journal, vol. 45, no.
1, pg.
9-17, February 1994; or William A. Buskirk et al., Development of a High Resolution Thermal Inkiet Printhead, Hewlett-Packard Journal, vol. 39, no. 5, pg.
55-61, October 1988.
[0014] Fluid ejection device 102 described in the present invention can reproducibly and reliably eject drops in the range of from about 1 alto-liter to about 1 pico-liters depending on the parameters of the fluid ejection device such as the size and geometry of the chamber around the fluid ejector, the size and geometry of the fluid ejector, and the size and geometry of the nozzle. In an alternate embodiment, utilizing what is generally referred to as a "direct drive" fluid ejection device, drops in the range from about 1 atto-liter to about 100 pico-liters also may be utilized. In addition, in still other embodiments, drops in the range from about 5 femto-liters to about 1 micro-liter also may be utilized. Fluid ejection device 102 differs from conventional fluid ejectors such as hydraulic, air assisted, or ultrasonic nozzles in that rather than forming a spray of fluid having varying drop sizes, this embodiment, utilizes a drop generator that creates fixed-sized drops that are discretely ejected. Fig. 1b is a graph describing the normalized distribution of drop volume for conventional fluid ejectors utilizing hydraulic, air assisted, or ultrasonic nozzles. The particular drop volume distribution depends on the nozzle type and generally varies from one type to another. In addition, other factors such as the fluid properties, nozzle capacity, and spraying pressure also effect the drop volume. As is illustrated in Fig. 1 b conventional fluid ejectors generally have a broad distribution of drop volumes. Fluid ejection device 102 differs from conventional fluid ejectors in that rather than forming a spray of fluid having varying drops volumes, activation of drop ejector 126 generates substantially fixed size drops that are discretely ejected. Fluid ejection device 102, on the other hand utilizes a method of creating discrete sized drops that are independently ejected from a particular nozzle utilizing a particular fluid ejector while maintaining a narrow drop volume distribution as shown in Fig. 1c. In addition, the narrow drop volume distribution is maintained over multiple nozzles each having a separate fluid ejector and fired independently or simultaneously. As can be seen comparing Figs. 1 b and 1 c the present invention has a very narrow distribution of drop volumes and may have anywhere from a 2X, 3X or even more narrower drop volume distribution than conventional fluid ejectors. In this embodiment, the range in drop volume is generally within 10 percent of the targeted or specified value and under steady state conditions is within about 6 percent of the targeted value. Because of the narrow (near uniform) distribution of ejected drops from fluid ejector device 102, the distribution of the size of the microcapsules, formed from the ejected drops, have a corresponding narrow distribution in size. Thus, the present invention has the ability to accurately dispense a fluid including a core material component with a part per million to a part per billion accuracy. This is particularly advantageous when dispensing substances that have a high preparation cost. For example, materials such as certain proteins, peptides, hormones, antibiotics, and bioactive fluids derived from some natural products in scarce supply may be effectively dispensed and formed into microcapsules utilizing such a fluid ejection device. In addition, the accuracy and precision is advantageous when dispensing concentrated substances, such as pharmaceuticals with high potency.
[0015] In the present invention microcapsules may have a variety of structures. For example, some may have a substantially spherical shape with a substantially continuous core region or core material 250 surrounded by substantially continuous shell material 252 as illustrated, in a cross-sectional view, in Fig. 2a. Although Fig. 2a depicts microcapsule 290 having a substantially spherical shape, microcapsule 210, in alternate embodiments, also may be formed having more oblate or prolate structures as well. In addition, continuous shell 252 as depicted in Fig. 2a has a uniform thickness, however, in alternate embodiments, continuous shell 252 also may have both a variation in shell thickness within a single microcapsule as well as variations in thickness from one microcapsule to another microcapsule. Another example of a microcapsule that may be formed utilizing the present invention is one having an irregular geometry containing a number of small droplets or particles of the core material component (i.e.
core material 250) dispersed within shell material 252 to form microcapsule 212 as illustrated in a cross-sectional view in Fig. 2b.
core material 250) dispersed within shell material 252 to form microcapsule 212 as illustrated in a cross-sectional view in Fig. 2b.
[0016] A flow diagram of a general method of manufacturing microcapsules, according to an embodiment of the present invention, is shown in Fig. 3. Fluid ejector activating process 390 is utilized to provide the desired amount of energy that initiates the drop forming process and depends on the particular type of fluid ejector utilized. For example, thermal fluid ejectors utilize pulses generally on the order of a few micro-seconds in duration providing a high to moderate current with moderate voltage when compared to piezoelectric fluid ejectors utilizing longer timed pulses providing very low current but moderate to higher voltage pulses. Electrostatic drop on demand type fluid ejectors, in contrast, utilize high voltage, low-power pulses, whereas acoustic fluid ejectors utilize radio frequency pulse bursts. Continuous fluid ejectors generally utilize three different sets of pulses, a low-power pulse for charging each nozzle through which drops are ejected, a periodic pulse of moderate power to synchronize drop break up, and a low power higher voltage pulse to deflect the fluid drops. The deflection of fluid drops is utilized to select which drops are recirculated and which drops are ejected from the device.
[001 ~ Fluid drop ejection process 392 is utilized to generate the force to eject a drop of fluid from a nozzle. Fluid drop ejection process 392 also depends on the particular type of fluid ejector utilized. For example, a thermal fluid ejector rapidly heats a component of the fluid above its boiling point causing vaporization of the fluid component generating a bubble whose expansion results in the ejection of a drop of the fluid. A piezoelectric transducer, on the other hand, utilizes a voltage pulse to generate a compressive force on the fluid resulting in ejection of a drop of the fluid through a nozzle. In contrast a continuous fluid ejector utilizes a fluid held under pressure in a chamber having a nozzle or bore to form a fluid jet that generally utilizes a piezoelectric vibrator attached to a wall of the chamber to generate the perturbation that causes the jet to breakup into drops. Any of these fluid ejector devices may be utilized in the present invention to eject a drop of a fluid that includes a core component or core material into a second fluid.
(0018] Microcapsule generating process 394 is utilized to form, in the second fluid, a microcapsule that includes the core material or core component.
The particular process depends on the particular chemistry utilized to form the microcapsule. In one embodiment, a complex coacervation process occurs where cationic and anionic water-soluble polymers interact in water to form a liquid, polymer rich phase called a complex coacervate. For example, a water insoluble core component material such as a bioactive substance is dispersed using a dispersing agent forming a first fluid. The frrst fluid including the dispersed insoluble core component material is ejected or dispensed into the second fluid to form an emulsion of core material in the second aqueous based solution utilizing fluid drop ejection process 392. In this example the second fluid is an aqueous gelatin solution held at a temperature of 35-65 °C that contains a buffer solution maintaining the pH of the solution between 4.0 and 5Ø While maintaining the temperature above the melting point of the gelatin a polyanion polymer (e.g.
natural or synthetic) may be added to the emulsion containing the core .material and gelatin to form a complex coacervate. In this example a negatively charged polymer like gum arabic may be added to the heated emulsion. Cooling the solution to room temperature allows the gelatin in the coacervate to gel forming microcapsules of the bioactive core material surrounded by the rubbery gelatin shell. Although such microcapsules have a continuous gelatin shell formed around the core materials, generally the shell is not uniform in thickness. Depending on the particular application in which the microcapsules are utilized it also may be desirable to increase the strength of the gelatin shell of the microcapsules by further treating 5 the microcapsules with a cross-linking agent such as glutaraldehyde. In addition, post treatment of the microcapsules with urea and formaldehyde under acidic conditions may be utilized to increase the resistance of the microcapsules to swelling in a moisture environment. In alternate embodiments, the polyanion polymer may be added to the first fluid that includes the dispersed insoluble core 10 component and ejected into the second fluid. This embodiment eliminates the step of adding the polyanion to the emulsion formed by ejecting the dispersed core component into the second fluid. Complex coacervation may be utilized to form microcapsules of many liquids.
[0019] Complex coacervation utilizes two oppositely charged polymers, i.e. a cationic and an anionic species where both species are incorporated into the microcapsule. However, in an alternate embodiment, two incompatible polymers also may be utilized, to form microcapsules as well. For example, for core materials that are degraded neither by temperatures of 70-80 °C nor by the use of a solvent such as cyclohexane the core material may be dispersed, using an appropriate dispersing agent, in a cyclohexane ethycellulose solution and ejected into a second solution of cyclohexane including a non-polar. polymer such as polyethylene to form a two phase system with a common solvent. When the system is cooled the ethyl cellulose solidifies and the microcapsules may be separated. Aspirin and potassium chloride are two examples of core materials that may be formed into microcapsules utilizing polymer incompatibility as a micro-encapsulation technique. A biodegradable shell utilizing poly(d,1-lactide-glycolide) also may be prepared using this technique.
[0020] In an alternate embodiment, an interfacial reaction may be induced at or on the surface of a drop ejected from a fluid ejector. For example, a water immiscible core component liquid includes a monomer dissolved in the core component liquid. The particular monomer utilized will depend on the particular application in which the microcapsules will be used, various monomers such as isocyanates, acid chlorides as well as combinations or mixtures of monomers all may be utilized. The core component liquid is ejected into a second aqueous solution that includes a co-reactant to the monomer added to the core component liquid. The co-reactant reacts with the monomer at the interface to form a microcapsule shell. The particular co-reactant utilized depends on the particular monomer dissolved in the core component liquid. A polyurea shell is formed between an amine co-reactant and an isocyanate monomer, whereas a polyamide shell is formed between an amine co-reactant and an acid chloride monomer. A
polyurethane shell may be formed between the reaction of a hydroxyl containing co-reactant and an isocyanate monomer. In those cases where the core component material is an aqueous solution the monomer is generally an amine or other aqueous soluble monomer and the co-reactant is dissolved in a water immiscible solvent as the second fluid.
(0021] In still other embodiments, the second fluid, into which the ejected drops are dispensed, may be stirred or flowed across the face of the fluid ejector device in a direction perpendicular to the fluid ejection axis (see fluid ejection axis 148 in Fig. 1 ) with the nozzle or nozzles of the fluid ejector device disposed either a pre-selected distance above the second fluid or inserted into the second fluid a pre-selected amount. For example, a fluid ejection device may eject drops onto a thin fluid sheet that may be flowing past the fluid ejector device. In still other embodiments, the second fluid may remain stationary while the fluid ejector device is scanned or moved laterally over or within the second liquid utilizing mechanisms similar to those used in ink jet printing devices. In an alternative embodiment, the second fluid into which the ejected drops are dispensed may be provided as a mist such as is generated by a spinning plate or wheel humidifier type device or compression ejection or other means in which the mist is directed into or across the path of drop 146 (see Fig. 1 a). In still another embodiment, a mist of the second fluid may be generated utilizing a fluid ejection device similar to that described in Fig. 1 a where the reservoir contains the second fluid.
[0022] In an exemplary embodiment of the present invention microcapsule generating process 394 utilizes chitosan calcium alginate microcapsules to encapsulate hemoglobin, cells, enzymes, or other biological molecules under mild conditions that maintains the activity of the biological macromolecules. In this embodiment, sodium alginate is dissolved, in an aqueous solution containing hemoglobin in the range from about 25 grams/liter to about 200 grams/liter, to obtain a final concentration of sodium alginate of about 1.8% weight of sodium alginate to volume of hemoglobin solution. The particular amount of hemoglobin utilized depends on the particular application in which the microcapsules will be utilized. The solution is then added to the reservoir of a fluid ejector device and then ejected as drops into a second aqueous fluid containing chitosan in the range from about 6 grams per liter to about 10 grams per liter. The particular amount of chitosan utilized will depend on various parameters such as the storage time of the capsules, the amount of hemoglobin being encapsulated, and whether the microcapsules are simultaneously or subsequently treated with calcium chloride.
In addition, the chitosan solution includes 0.1% hydrochloric acid. In this embodiment, the chitosan solution also contains a 0.005 M CaCl2 solution and the pH of the entire chitosan, hemoglobin, CaClz solution is adjusted to have a value in the range from about 4.0 to 6.0 with 1 M NaOH. In an alternate embodiment, other salts having divalent or trivalent cations such as magnesium chloride, barium chloride, and aluminum sulfate also may be utilized. The chitosan alginate microcapsules are allowed to gel and harden for approximately 30 mins in the presence of the CaCl2 before being isolated. In an alternate embodiment, the chitosan alginate microcapsules are formed in the chitosan 0.1 % HCI solution and isolated. The isolated microcapsules are then treated with a 0.005 M CaCl2 solution having a pH of 5.4 utilizing NaOH. The particular concentrations and the particular pH at which the microcapsules are formed will depend on the particular application in which the microcapsules will be utilized because the characteristics of the chitosan solution have been found to influence the hemoglobin permeability of the microcapsules. For example, the solution viscosity, pH, and molecular weight of the chitosan may each effect the permeability of the microcapsules.
In still other embodiments, the alginate microcapsules may be further treated with poly-I-lysine, which will harden the outer shell of the microcapsules and prevent alginate untangling in a dilute solution.
[0023 In an alternate embodiment of the present invention chitosan calcium alginate microcapsules are formed to encapsulate protein and peptide drugs that are susceptible to enzymatic attack and acidic hydrolysis in the gastrointestinal region if orally administered. In this embodiment, a 2% (w/v) solution of sodium alginate and a 1 % (w/w) solution of bovine serum albumin are mixed and the pH of the solution is adjusted to 5.5. In this embodiment, bovine serum albumin is utilized as a model representative of various protein or peptide drugs that may be encapsulated. Examples of proteins that may be utilized are interferons, interleukins, darbepoetins, ethanercept, epogens, activases, and dornases. Examples of peptides that may be utilized are gonadotropins, lisinopril, calcitonin, ocreotide, leuprolide, and glucagons family peptides. The alginate, bovine serum albumin solution is then added to the reservoir of a fluid ejector device and ejected as drops into a second aqueous fluid. The second aqueous fluid includes a 1 % (w/v) chitosan solution dissolved in a 1 % (v/v) acetic acid solution at room temperature. The second aqueous fluid is then diluted with an aqueous 3% CaCl2 solution and the pH adjusted to 4.5 to obtain a second aqueous fluid having chitosan in the range from about 0.2% (w/v) to about 0.8% (w/v).
The microcapsules are obtained by filtering, washing with distilled water, and then allowed to air dry. In still other embodiments, multilayer microcapsules may be formed by filtering and washing the initially formed microcapsules with distilled water followed by subsequent transfer to a stirred solution having chitosan in the range from about 0.02% to about 0.08%. The chitosan-alginate multilayer microcapsules are then transferred to a 0.5% CaCl2 aqueous solution for about minutes. These multilayer microcapsules generally show an increased delay in the release of entrapped protein compared to microcapsules formed in a single step.
[0024 In still another embodiment living cells suspended in sodium alginate solution are dispensed from a thermal inkjet (TIJ) device into water containing calcium chloride, thereby producing microcapsules containing encapsulated living cells. Lactobacillus acidophilus and Lactobacillus bulgaricus are isolated from Lactinex~, a commercially available tablet for treatment of intestinal disorders, and grown to a total cell count of about 1 x 10'°
in a suitable liquid laboratory nutrient medium broth. For all viable cell counting, cell chains and clumps are broken using a suitable blender such as a Waring blender. Sodium alginate (2 grams) is autoclaved and then added into 100 ml of the mature bacterial growth medium while slowly stirring. The bacterial cell preparation is dispensed from a sterile TIJ device into a sterilized aqueous solution containing one-molar calcium chloride. In this embodiment the second fluid or receptor fluid is a continuous thin liquid film where either the thin film is flowing perpendicular to the fluid ejection axis of the fluid ejection device or the fluid ejection device is scanned or moved laterally over the receptor thin film. The microcapsules containing living cells are collected or removed from the receptor fluid by centrifuging or by filtration with the calcium chloride receptor solution recycled and utilized to form additional microcapsules. In alternate embodiments, the calcium chloride receptor fluid is rapidly mixed with "top to bottom" mixing or stirring. Generally, over 80% of the cells in the growth medium/alginate mixture, are entrapped and viable in the microcapsule slurry collected by centrifugation. The microcapsules containing living cells may be used in the "wet" form as collected or may be dried, generally under vacuum and controlled temperature to minimize cell damage. In alternate embodiments, other drying techniques also may be utilized. The microcapsules containing the entrapped living cells are placed in gelatin capsules that are enteric coated and administered orally to mammals as intestinal tract microbial replacement or establishment therapy. In alternate embodiments, cells entrapped 5 in microcapsules are utilized to inoculate milk to produce cheese.
Streptococcus thermophilius, Bifidobactria, pancreatic cells, and red blood cells are just a few examples of other living cells, with isotonic adjustment as needed, that may be encapsulated utilizing the present invention [0025] What is Claimed is:
[001 ~ Fluid drop ejection process 392 is utilized to generate the force to eject a drop of fluid from a nozzle. Fluid drop ejection process 392 also depends on the particular type of fluid ejector utilized. For example, a thermal fluid ejector rapidly heats a component of the fluid above its boiling point causing vaporization of the fluid component generating a bubble whose expansion results in the ejection of a drop of the fluid. A piezoelectric transducer, on the other hand, utilizes a voltage pulse to generate a compressive force on the fluid resulting in ejection of a drop of the fluid through a nozzle. In contrast a continuous fluid ejector utilizes a fluid held under pressure in a chamber having a nozzle or bore to form a fluid jet that generally utilizes a piezoelectric vibrator attached to a wall of the chamber to generate the perturbation that causes the jet to breakup into drops. Any of these fluid ejector devices may be utilized in the present invention to eject a drop of a fluid that includes a core component or core material into a second fluid.
(0018] Microcapsule generating process 394 is utilized to form, in the second fluid, a microcapsule that includes the core material or core component.
The particular process depends on the particular chemistry utilized to form the microcapsule. In one embodiment, a complex coacervation process occurs where cationic and anionic water-soluble polymers interact in water to form a liquid, polymer rich phase called a complex coacervate. For example, a water insoluble core component material such as a bioactive substance is dispersed using a dispersing agent forming a first fluid. The frrst fluid including the dispersed insoluble core component material is ejected or dispensed into the second fluid to form an emulsion of core material in the second aqueous based solution utilizing fluid drop ejection process 392. In this example the second fluid is an aqueous gelatin solution held at a temperature of 35-65 °C that contains a buffer solution maintaining the pH of the solution between 4.0 and 5Ø While maintaining the temperature above the melting point of the gelatin a polyanion polymer (e.g.
natural or synthetic) may be added to the emulsion containing the core .material and gelatin to form a complex coacervate. In this example a negatively charged polymer like gum arabic may be added to the heated emulsion. Cooling the solution to room temperature allows the gelatin in the coacervate to gel forming microcapsules of the bioactive core material surrounded by the rubbery gelatin shell. Although such microcapsules have a continuous gelatin shell formed around the core materials, generally the shell is not uniform in thickness. Depending on the particular application in which the microcapsules are utilized it also may be desirable to increase the strength of the gelatin shell of the microcapsules by further treating 5 the microcapsules with a cross-linking agent such as glutaraldehyde. In addition, post treatment of the microcapsules with urea and formaldehyde under acidic conditions may be utilized to increase the resistance of the microcapsules to swelling in a moisture environment. In alternate embodiments, the polyanion polymer may be added to the first fluid that includes the dispersed insoluble core 10 component and ejected into the second fluid. This embodiment eliminates the step of adding the polyanion to the emulsion formed by ejecting the dispersed core component into the second fluid. Complex coacervation may be utilized to form microcapsules of many liquids.
[0019] Complex coacervation utilizes two oppositely charged polymers, i.e. a cationic and an anionic species where both species are incorporated into the microcapsule. However, in an alternate embodiment, two incompatible polymers also may be utilized, to form microcapsules as well. For example, for core materials that are degraded neither by temperatures of 70-80 °C nor by the use of a solvent such as cyclohexane the core material may be dispersed, using an appropriate dispersing agent, in a cyclohexane ethycellulose solution and ejected into a second solution of cyclohexane including a non-polar. polymer such as polyethylene to form a two phase system with a common solvent. When the system is cooled the ethyl cellulose solidifies and the microcapsules may be separated. Aspirin and potassium chloride are two examples of core materials that may be formed into microcapsules utilizing polymer incompatibility as a micro-encapsulation technique. A biodegradable shell utilizing poly(d,1-lactide-glycolide) also may be prepared using this technique.
[0020] In an alternate embodiment, an interfacial reaction may be induced at or on the surface of a drop ejected from a fluid ejector. For example, a water immiscible core component liquid includes a monomer dissolved in the core component liquid. The particular monomer utilized will depend on the particular application in which the microcapsules will be used, various monomers such as isocyanates, acid chlorides as well as combinations or mixtures of monomers all may be utilized. The core component liquid is ejected into a second aqueous solution that includes a co-reactant to the monomer added to the core component liquid. The co-reactant reacts with the monomer at the interface to form a microcapsule shell. The particular co-reactant utilized depends on the particular monomer dissolved in the core component liquid. A polyurea shell is formed between an amine co-reactant and an isocyanate monomer, whereas a polyamide shell is formed between an amine co-reactant and an acid chloride monomer. A
polyurethane shell may be formed between the reaction of a hydroxyl containing co-reactant and an isocyanate monomer. In those cases where the core component material is an aqueous solution the monomer is generally an amine or other aqueous soluble monomer and the co-reactant is dissolved in a water immiscible solvent as the second fluid.
(0021] In still other embodiments, the second fluid, into which the ejected drops are dispensed, may be stirred or flowed across the face of the fluid ejector device in a direction perpendicular to the fluid ejection axis (see fluid ejection axis 148 in Fig. 1 ) with the nozzle or nozzles of the fluid ejector device disposed either a pre-selected distance above the second fluid or inserted into the second fluid a pre-selected amount. For example, a fluid ejection device may eject drops onto a thin fluid sheet that may be flowing past the fluid ejector device. In still other embodiments, the second fluid may remain stationary while the fluid ejector device is scanned or moved laterally over or within the second liquid utilizing mechanisms similar to those used in ink jet printing devices. In an alternative embodiment, the second fluid into which the ejected drops are dispensed may be provided as a mist such as is generated by a spinning plate or wheel humidifier type device or compression ejection or other means in which the mist is directed into or across the path of drop 146 (see Fig. 1 a). In still another embodiment, a mist of the second fluid may be generated utilizing a fluid ejection device similar to that described in Fig. 1 a where the reservoir contains the second fluid.
[0022] In an exemplary embodiment of the present invention microcapsule generating process 394 utilizes chitosan calcium alginate microcapsules to encapsulate hemoglobin, cells, enzymes, or other biological molecules under mild conditions that maintains the activity of the biological macromolecules. In this embodiment, sodium alginate is dissolved, in an aqueous solution containing hemoglobin in the range from about 25 grams/liter to about 200 grams/liter, to obtain a final concentration of sodium alginate of about 1.8% weight of sodium alginate to volume of hemoglobin solution. The particular amount of hemoglobin utilized depends on the particular application in which the microcapsules will be utilized. The solution is then added to the reservoir of a fluid ejector device and then ejected as drops into a second aqueous fluid containing chitosan in the range from about 6 grams per liter to about 10 grams per liter. The particular amount of chitosan utilized will depend on various parameters such as the storage time of the capsules, the amount of hemoglobin being encapsulated, and whether the microcapsules are simultaneously or subsequently treated with calcium chloride.
In addition, the chitosan solution includes 0.1% hydrochloric acid. In this embodiment, the chitosan solution also contains a 0.005 M CaCl2 solution and the pH of the entire chitosan, hemoglobin, CaClz solution is adjusted to have a value in the range from about 4.0 to 6.0 with 1 M NaOH. In an alternate embodiment, other salts having divalent or trivalent cations such as magnesium chloride, barium chloride, and aluminum sulfate also may be utilized. The chitosan alginate microcapsules are allowed to gel and harden for approximately 30 mins in the presence of the CaCl2 before being isolated. In an alternate embodiment, the chitosan alginate microcapsules are formed in the chitosan 0.1 % HCI solution and isolated. The isolated microcapsules are then treated with a 0.005 M CaCl2 solution having a pH of 5.4 utilizing NaOH. The particular concentrations and the particular pH at which the microcapsules are formed will depend on the particular application in which the microcapsules will be utilized because the characteristics of the chitosan solution have been found to influence the hemoglobin permeability of the microcapsules. For example, the solution viscosity, pH, and molecular weight of the chitosan may each effect the permeability of the microcapsules.
In still other embodiments, the alginate microcapsules may be further treated with poly-I-lysine, which will harden the outer shell of the microcapsules and prevent alginate untangling in a dilute solution.
[0023 In an alternate embodiment of the present invention chitosan calcium alginate microcapsules are formed to encapsulate protein and peptide drugs that are susceptible to enzymatic attack and acidic hydrolysis in the gastrointestinal region if orally administered. In this embodiment, a 2% (w/v) solution of sodium alginate and a 1 % (w/w) solution of bovine serum albumin are mixed and the pH of the solution is adjusted to 5.5. In this embodiment, bovine serum albumin is utilized as a model representative of various protein or peptide drugs that may be encapsulated. Examples of proteins that may be utilized are interferons, interleukins, darbepoetins, ethanercept, epogens, activases, and dornases. Examples of peptides that may be utilized are gonadotropins, lisinopril, calcitonin, ocreotide, leuprolide, and glucagons family peptides. The alginate, bovine serum albumin solution is then added to the reservoir of a fluid ejector device and ejected as drops into a second aqueous fluid. The second aqueous fluid includes a 1 % (w/v) chitosan solution dissolved in a 1 % (v/v) acetic acid solution at room temperature. The second aqueous fluid is then diluted with an aqueous 3% CaCl2 solution and the pH adjusted to 4.5 to obtain a second aqueous fluid having chitosan in the range from about 0.2% (w/v) to about 0.8% (w/v).
The microcapsules are obtained by filtering, washing with distilled water, and then allowed to air dry. In still other embodiments, multilayer microcapsules may be formed by filtering and washing the initially formed microcapsules with distilled water followed by subsequent transfer to a stirred solution having chitosan in the range from about 0.02% to about 0.08%. The chitosan-alginate multilayer microcapsules are then transferred to a 0.5% CaCl2 aqueous solution for about minutes. These multilayer microcapsules generally show an increased delay in the release of entrapped protein compared to microcapsules formed in a single step.
[0024 In still another embodiment living cells suspended in sodium alginate solution are dispensed from a thermal inkjet (TIJ) device into water containing calcium chloride, thereby producing microcapsules containing encapsulated living cells. Lactobacillus acidophilus and Lactobacillus bulgaricus are isolated from Lactinex~, a commercially available tablet for treatment of intestinal disorders, and grown to a total cell count of about 1 x 10'°
in a suitable liquid laboratory nutrient medium broth. For all viable cell counting, cell chains and clumps are broken using a suitable blender such as a Waring blender. Sodium alginate (2 grams) is autoclaved and then added into 100 ml of the mature bacterial growth medium while slowly stirring. The bacterial cell preparation is dispensed from a sterile TIJ device into a sterilized aqueous solution containing one-molar calcium chloride. In this embodiment the second fluid or receptor fluid is a continuous thin liquid film where either the thin film is flowing perpendicular to the fluid ejection axis of the fluid ejection device or the fluid ejection device is scanned or moved laterally over the receptor thin film. The microcapsules containing living cells are collected or removed from the receptor fluid by centrifuging or by filtration with the calcium chloride receptor solution recycled and utilized to form additional microcapsules. In alternate embodiments, the calcium chloride receptor fluid is rapidly mixed with "top to bottom" mixing or stirring. Generally, over 80% of the cells in the growth medium/alginate mixture, are entrapped and viable in the microcapsule slurry collected by centrifugation. The microcapsules containing living cells may be used in the "wet" form as collected or may be dried, generally under vacuum and controlled temperature to minimize cell damage. In alternate embodiments, other drying techniques also may be utilized. The microcapsules containing the entrapped living cells are placed in gelatin capsules that are enteric coated and administered orally to mammals as intestinal tract microbial replacement or establishment therapy. In alternate embodiments, cells entrapped 5 in microcapsules are utilized to inoculate milk to produce cheese.
Streptococcus thermophilius, Bifidobactria, pancreatic cells, and red blood cells are just a few examples of other living cells, with isotonic adjustment as needed, that may be encapsulated utilizing the present invention [0025] What is Claimed is:
Claims (72)
1. ~A method of making a microcapsule, comprising:
activating a fluid ejector at a frequency greater than 10 kilohertz, wherein each activation of said fluid ejector generates essentially a drop, said fluid ejector fluidically coupled to a first fluid including a core component;
ejecting essentially said drop of said first fluid into a second fluid, said drop having a volume; and generating a microcapsule in said second fluid for each drop of said first fluid ejected, wherein said microcapsule includes said core component.
activating a fluid ejector at a frequency greater than 10 kilohertz, wherein each activation of said fluid ejector generates essentially a drop, said fluid ejector fluidically coupled to a first fluid including a core component;
ejecting essentially said drop of said first fluid into a second fluid, said drop having a volume; and generating a microcapsule in said second fluid for each drop of said first fluid ejected, wherein said microcapsule includes said core component.
2. ~The method in accordance with the method of claim 1, wherein activating said fluid ejector further comprises activating a drop on demand fluid ejector.
3. ~The method in accordance with the method of claim 2, wherein activating said fluid ejector further comprises:
activating a thermal resistor; and heating at least one component of said first fluid above the boiling point of said at least one component.
activating a thermal resistor; and heating at least one component of said first fluid above the boiling point of said at least one component.
4. ~The method in accordance with the method of claim 1, wherein activating said fluid ejector actuator further comprises activating a fluid ejector energy generating element n times, ejecting n drops of said first fluid into said second fluid, wherein n is an integer.
5. ~The method in accordance with the method of claim 4, wherein said n drops produce a distribution of drop volumes within 10 percent of a specified volume.
6. ~The method in accordance with the method of claim 4, further comprising activating said fluid ejector energy generating element at a steady state producing a distribution of drop volumes within 6 percent of a specified volume.
7. ~The method in accordance with the method of claim 1, wherein said volume of said drop is in the range from about 1 alto-liter to about 100 pico-liters.
8. ~The method in accordance with the method of claim 1, wherein said volume of said drop is in the range from about 1 alto-liter to about 1 pico-liters.
9. ~The method in accordance with the method of claim 1, wherein activating said fluid ejector further comprises activating a thermal resistor.
10. ~The method in accordance with the method of claim 1, wherein activating said fluid ejector further comprises activating a piezoelectric element.
11. ~The method in accordance with the method of claim 1, wherein activating said fluid ejector further comprises activating said fluid ejector at a frequency greater than 20 kilohertz.
12. ~The method in accordance with the method of claim 1, wherein activating said fluid ejector further comprises:
applying an electrical pulse charging a nozzle through which said first fluid is ejected; and applying a voltage pulse to deflect a pre-selected number of drops.
applying an electrical pulse charging a nozzle through which said first fluid is ejected; and applying a voltage pulse to deflect a pre-selected number of drops.
13. ~The method in accordance with the method of claim 12, further comprising deflecting a pre-selected number of said drops into a recirculator.
18~
18~
14. ~The method in accordance with the method of claim 1, wherein ejecting said drop further comprises ejecting said drop a pre-selected distance above the surface of said second fluid.
15. ~The method in accordance with the method of claim 14. further comprising ejecting said drop of said first fluid into a thin liquid film of said second fluid.
16. ~The method in accordance with the method of claim 15, further comprising flowing said thin liquid film of said second fluid in a direction perpendicular to a fluid ejection axis of a fluid ejector head.
17. ~The method in accordance with the method of claim 1, wherein ejecting said drop further comprises ejecting said drop of said first fluid from a chamber through at least one nozzle formed in a nozzle layer, said chamber and said at least one nozzle each having a volume, wherein said volume of said chamber is greater than said volume of said nozzle.
18. ~The method in accordance with the method of claim 1, wherein ejecting said drop further comprises ejecting said drop of said first fluid from at least one nozzle formed in a nozzle layer.
19. ~The method in accordance with the method of claim 18, further comprising immersing said at least one nozzle wherein at least a portion of said nozzle layer is below the surface of said second fluid.
20. ~The method in accordance with the method of claim 19, further comprising flowing said second fluid in a direction perpendicular to a fluid ejection axis of a fluid ejector head.
21. The method in accordance with the method of claim 1, further comprising:
moving said fluid ejector in at least one lateral direction over said second fluid;
activating said fluid ejector at pre-selected lateral locations; and ejecting essentially a drop of said first fluid into said second fluid at each pre-selected lateral location.
moving said fluid ejector in at least one lateral direction over said second fluid;
activating said fluid ejector at pre-selected lateral locations; and ejecting essentially a drop of said first fluid into said second fluid at each pre-selected lateral location.
22. The method in accordance with the method of claim 20, wherein moving said fluid ejector further comprises reciprocally translating said fluid ejector over said second fluid.
23. The method in accordance with the method of claim 1, further comprising flowing said second fluid in a thin film in a direction perpendicular to a fluid ejection axis of said fluid ejector.
24. The method in accordance with the method of claim 1, further comprising:
moving said fluid ejector in at least one lateral direction in said second fluid;
activating said fluid ejector at pre-selected lateral locations; and ejecting essentially a drop of said first fluid into said second fluid at each pre-selected lateral location.
moving said fluid ejector in at least one lateral direction in said second fluid;
activating said fluid ejector at pre-selected lateral locations; and ejecting essentially a drop of said first fluid into said second fluid at each pre-selected lateral location.
25. The method in accordance with the method of claim 20, wherein moving said fluid ejector further comprises reciprocally translating said fluid ejector in a lateral direction in said second fluid.
26. The method in accordance with the method of claim 1, wherein ejecting said drop further comprises ejecting essentially said drop of said first fluid into a mist of said second fluid.
27. The method in accordance with the method of claim 26, further comprising:
activating a plurality of second fluid ejectors fluidically coupled to said second fluid;
ejecting multiple second fluid drops of said second fluid proximate to said drop of said first fluid; and generating said mist of said second fluid.
activating a plurality of second fluid ejectors fluidically coupled to said second fluid;
ejecting multiple second fluid drops of said second fluid proximate to said drop of said first fluid; and generating said mist of said second fluid.
28. The method in accordance with the method of claim 27, wherein said multiple second fluid drops of said second fluid produce a distribution of second fluid drop volumes within 10 percent of a specified second fluid drop volume.
29. The method in accordance with the method of claim 1, wherein ejecting said drop further comprises ejecting said drop of said first fluid having a polyanion, wherein said core component is dispersed in said first fluid.
30. The method in accordance with the method of claim 1, wherein ejecting said first drop further comprises ejecting a drop of a first fluid immiscible with said second fluid.
31. The method in accordance with the method of claim 1, wherein said core component includes a bioactive agent.
32. The method in accordance with the method of claim 1, wherein ejecting said drop further comprises ejecting a drop of a first fluid including said core component and a monomer into a second fluid that includes a co-reactant to said monomer.
33. The method in accordance with the method of claim 32, further comprising reacting said monomer and said co-reactant to form a polymer shell encapsulating said core component.
34. The method in accordance with the method of claim 1, wherein said core component includes hemoglobin.
35. The method in accordance with the method of claim 1, wherein said core component includes a red blood cell.
36. The method in accordance with the method of claim 1, wherein said core component includes a living cell.
37. The method in accordance with the method of claim 1, wherein said core component includes a protein.
38. The method in accordance with the method of claim 1, wherein said core component includes a peptide.
39. The method in accordance with the method of claim 1, wherein generating a microcapsule further comprises generating a chitosan alkali metal alginate microcapsule.
40. The method in accordance with the method of claim 1, wherein generating said microcapsule further comprises forming a coacervate.
41. The method in accordance with the method of claim 1, wherein generating said microcapsule further comprises encapsulating hemoglobin.
42. The method in accordance with the method of claim 1, wherein generating said microcapsule further comprises encapsulating red blood cells.
43. The method in accordance with the method of claim 1, wherein generating said microcapsule further comprises encapsulating a living cell.
44. The method in accordance with the method of claim 1, wherein generating said microcapsule further comprises encapsulating a protein.
45. The method in accordance with the method of claim 1, wherein generating said microcapsule further comprises encapsulating a peptide.
46. A method of making a microcapsule, comprising:
activating n times a drop-on-demand fluid ejector, said fluid ejector fluidically coupled to a first fluid including a core component, said fluid ejector operated at a frequency greater than 10 kilohertz, wherein each activation generates essentially a fluid drop of said first fluid;
ejecting essentially n drops of said first fluid into a second fluid producing a distribution of n fluid drop volumes, wherein each drop volume of said n fluid drops is within about 10 percent of a specified drop volume; and generating a microcapsule in said second fluid, wherein said microcapsule includes said core component.
activating n times a drop-on-demand fluid ejector, said fluid ejector fluidically coupled to a first fluid including a core component, said fluid ejector operated at a frequency greater than 10 kilohertz, wherein each activation generates essentially a fluid drop of said first fluid;
ejecting essentially n drops of said first fluid into a second fluid producing a distribution of n fluid drop volumes, wherein each drop volume of said n fluid drops is within about 10 percent of a specified drop volume; and generating a microcapsule in said second fluid, wherein said microcapsule includes said core component.
47. A method of using a drop on demand fluid ejection device, comprising:
energizing the drop on demand fluid ejection device;
ejecting essentially a drop of a first fluid including a microcapsule forming core component into a second fluid; and generating a microcapsule in said second fluid, wherein said microcapsule includes said microcapsule forming core component.
energizing the drop on demand fluid ejection device;
ejecting essentially a drop of a first fluid including a microcapsule forming core component into a second fluid; and generating a microcapsule in said second fluid, wherein said microcapsule includes said microcapsule forming core component.
48. The method in accordance with the method of claim 47, wherein energizing the fluid ejection device further comprises energizing a thermally activated fluid ejection device.
49. The method in accordance with the method of claim 47, further comprising positioning the fluid ejection device a pre-selected distance above said second fluid.
50. The method in accordance with the method of claim 47, further comprising immersing the fluid ejection device a pre-selected distance in said second fluid.
51. The method in accordance with the method of claim 47, further comprising flowing said second fluid in a direction perpendicular to a fluid ejection axis of the fluid ejection device.
52. The method in accordance with the method of claim 51, further comprising:
moving the fluid ejection device in at least one lateral direction in said second fluid; and ejecting n drops of said first fluid into said second fluid at n pre-selected lateral locations.
moving the fluid ejection device in at least one lateral direction in said second fluid; and ejecting n drops of said first fluid into said second fluid at n pre-selected lateral locations.
53. The method in accordance with the method of claim 51, further comprising:
moving the fluid ejection device in at least one lateral direction over said second fluid; and ejecting n drops of said first fluid into said second fluid at n pre-selected lateral locations.
moving the fluid ejection device in at least one lateral direction over said second fluid; and ejecting n drops of said first fluid into said second fluid at n pre-selected lateral locations.
54. The method in accordance with the method of claim 53, wherein moving said fluid ejector further comprises reciprocally translating said fluid ejector over said second fluid.
55. The method in accordance with the method of claim 53, further comprising flowing said second fluid in a thin film in a direction perpendicular to a fluid ejection axis of said fluid ejector.
56. The method in accordance with the method of claim 47, wherein ejecting said drop further comprises ejecting said drop of said first fluid having a polyanion, wherein said core component is dispersed in said first fluid.
57. The method in accordance with the method of claim 47, wherein ejecting said first drop further comprises ejecting a drop of a first fluid immiscible with said second fluid.
58. The method in accordance with the method of claim 47, wherein said core component includes a bioactive agent.
59. The method in accordance with the method of claim 47, wherein ejecting said drop further comprises ejecting a drop of a first fluid including said core component and a monomer into a second fluid that includes a co-reactant to said monomer.
60. The method in accordance with the method of claim 59, further comprising reacting said monomer and said co-reactant to form a polymer shell encapsulating said core component.
61. The method in accordance with the method of claim 47, wherein said core component includes hemoglobin.
62. The method in accordance with the method of claim 47, wherein said core component includes a red blood cell.
63. The method in accordance with the method of claim 47, wherein said core component includes a living cell.
64. The method in accordance with the method of claim 47, wherein said core component includes a protein.
65. The method in accordance with the method of claim 47, wherein said core component includes a peptide.
66. The method in accordance with the method of claim 47, wherein generating a microcapsule further comprises generating a chitosan alkali metal alginate microcapsule.
67. The method in accordance with the method of claim 47, wherein generating said microcapsule further comprises forming a coacervate.
68. The method in accordance with the method of claim 47, wherein generating said microcapsule further comprises encapsulating hemoglobin.
69. The method in accordance with the method of claim 47, wherein generating said microcapsule further comprises encapsulating red blood cells.
70. The method in accordance with the method of claim 47, wherein generating said microcapsule further comprises encapsulating a living cell.
71. The method in accordance with the method of claim 47, wherein generating said microcapsule further comprises encapsulating a protein.
72. The method in accordance with the method of claim 47, wherein generating said microcapsule further comprises encapsulating a peptide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/765,402 | 2004-01-27 | ||
US10/765,402 US7578951B2 (en) | 2004-01-27 | 2004-01-27 | Method of making microcapsules utilizing a fluid ejector |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2494489A1 true CA2494489A1 (en) | 2005-07-27 |
CA2494489C CA2494489C (en) | 2013-08-13 |
Family
ID=34654318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2494489A Expired - Fee Related CA2494489C (en) | 2004-01-27 | 2005-01-26 | Method of making microcapsules utilizing a fluid ejector |
Country Status (8)
Country | Link |
---|---|
US (1) | US7578951B2 (en) |
EP (1) | EP1559476B1 (en) |
JP (1) | JP4526399B2 (en) |
KR (1) | KR101177782B1 (en) |
CN (1) | CN1669628A (en) |
CA (1) | CA2494489C (en) |
SG (1) | SG113550A1 (en) |
TW (1) | TWI327467B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7730746B1 (en) * | 2005-07-14 | 2010-06-08 | Imaging Systems Technology | Apparatus to prepare discrete hollow microsphere droplets |
EP1971426A1 (en) * | 2006-01-11 | 2008-09-24 | P & W Invest Vermögensverwaltungsgesellschaft mbH | Enveloping membrane for discharging an enclosed agent, method for the production thereof, and use thereof |
JP4974144B2 (en) * | 2006-11-20 | 2012-07-11 | 国立大学法人 東京医科歯科大学 | Gel production method and apparatus therefor |
KR100902781B1 (en) * | 2007-10-05 | 2009-06-12 | (주)라이프코드 | Integrated device for the preparation of aseptic capsules |
BRPI1016013A2 (en) | 2009-06-29 | 2016-04-26 | Mcneil Ppc Inc | pharmaceutical tablet containing a capsule filled with liquid. |
JP4715951B2 (en) * | 2009-07-16 | 2011-07-06 | セイコーエプソン株式会社 | Gel production equipment |
WO2011140106A1 (en) * | 2010-05-03 | 2011-11-10 | Eurand Pharmaceuticals Limited | Micropellet compositions comprising pancreatin containing digestive enzyme mixtures |
FR2996466B1 (en) * | 2012-10-09 | 2015-06-05 | Seppic Sa | METHOD OF ENCAPSULATION BY COACERVATION NOT IMPLEMENTING TOXIC RETICULANT |
CN105142913B (en) * | 2013-04-26 | 2017-10-27 | 科迪华公司 | For the method and apparatus to the measurement of pad-ink drop and control of deposits fluid in precision tolerances |
US10093096B2 (en) | 2014-07-31 | 2018-10-09 | Hewlett-Packard Development Company, L.P. | Maintenance of a printhead of a printer |
WO2016089371A1 (en) | 2014-12-02 | 2016-06-09 | Hewlett-Packard Development Company, L.P. | Printhead nozzle addressing |
CN109789383A (en) | 2016-10-21 | 2019-05-21 | 惠普发展公司,有限责任合伙企业 | Drop generator |
US10639607B2 (en) | 2017-06-16 | 2020-05-05 | Matralix Pte Ltd | Systems and methods for preparing wax and lipid particles |
JP6683274B2 (en) * | 2019-02-19 | 2020-04-15 | 大日本印刷株式会社 | Method for producing solid medicine, ink set for inkjet |
JP7408217B2 (en) * | 2020-06-01 | 2024-01-05 | エルジー・ケム・リミテッド | Method for producing polymeric microparticles, polymeric microparticles, medical compositions containing the same, beauty compositions, medical supplies, and beauty products |
CN111701545B (en) * | 2020-06-04 | 2022-03-25 | 上海工程技术大学 | Dripping pill production system suitable for producing microcapsule formula soil conditioner |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3946398A (en) * | 1970-06-29 | 1976-03-23 | Silonics, Inc. | Method and apparatus for recording with writing fluids and drop projection means therefor |
JPS5211180A (en) | 1975-07-17 | 1977-01-27 | New Japan Chem Co Ltd | Process of covering dispersed particles |
US4548825A (en) * | 1978-11-15 | 1985-10-22 | Boehringer Ingelheim Gmbh | Method for ink-jet printing on uncoated tablets or uncoated tablet cores |
DE2849494A1 (en) * | 1978-11-15 | 1980-05-29 | Voss Gunter M | METHOD FOR THE PRODUCTION OF MEDICINAL FORMS |
JPS5849433A (en) * | 1981-09-18 | 1983-03-23 | Tanabe Seiyaku Co Ltd | Production of microcapsule |
US4692284A (en) * | 1986-04-30 | 1987-09-08 | Damon Biotech, Inc. | Method and apparatus for forming droplets and microcapsules |
US4877745A (en) * | 1986-11-17 | 1989-10-31 | Abbott Laboratories | Apparatus and process for reagent fluid dispensing and printing |
JPS63236534A (en) | 1987-03-17 | 1988-10-03 | サウスウエスト・リサ−チ・インステイテユ−ト | Method and apparatus for mass production of seamless capsule |
US5395620A (en) * | 1989-01-31 | 1995-03-07 | Coletica | Biodegradable microcapsules having walls composed of crosslinked atelocollagen and polyholoside |
US5260002A (en) * | 1991-12-23 | 1993-11-09 | Vanderbilt University | Method and apparatus for producing uniform polymeric spheres |
BR9406968A (en) * | 1993-06-29 | 1996-08-06 | Voges Innovation Pty Ltd | Dispenser |
JP3053325B2 (en) * | 1993-12-20 | 2000-06-19 | 株式会社日立製作所 | Corrosion potential simulation method and reactor plant operation monitoring device |
US6558633B1 (en) * | 1994-09-21 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Chemical reaction apparatus and methods |
WO1996028247A1 (en) | 1995-03-15 | 1996-09-19 | Inotech Ag | Encapsulation equipment |
DE19535010C2 (en) * | 1995-09-21 | 1998-01-22 | Pelikan Produktions Ag | Use of a drop generator in a medical device for the metered delivery of a medicament to a fluid stream |
US6555156B1 (en) * | 1998-01-29 | 2003-04-29 | Kinerton Limited | Process for making absorbable microparticles |
CA2327716A1 (en) * | 1998-03-07 | 1999-09-10 | Inotech Ag | Method and device for capsulating microbial, plant and animal cells or biological and chemical substances |
DE19813011A1 (en) | 1998-03-25 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Process for the production of microcapsules |
US6474786B2 (en) * | 2000-02-24 | 2002-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Micromachined two-dimensional array droplet ejectors |
DE10024154A1 (en) | 2000-05-19 | 2001-11-22 | Inotech Encapsulation Ag Dotti | Encapsulation of cells/substances uses an injection pump to form small spherical particles in an immobilizing mixture with external vibration on the pump and an electrical field at the hardening vessel |
US6599627B2 (en) * | 2000-12-13 | 2003-07-29 | Purdue Research Foundation | Microencapsulation of drugs by solvent exchange |
US6841593B2 (en) * | 2001-07-05 | 2005-01-11 | Baker Hughes Incorporated | Microencapsulated and macroencapsulated drag reducing agents |
JP3768885B2 (en) | 2002-01-08 | 2006-04-19 | 花王株式会社 | Easily disintegrating particle production system |
US6641254B1 (en) * | 2002-04-12 | 2003-11-04 | Hewlett-Packard Development Company, L.P. | Electronic devices having an inorganic film |
-
2004
- 2004-01-27 US US10/765,402 patent/US7578951B2/en not_active Expired - Fee Related
- 2004-07-22 EP EP04017408.8A patent/EP1559476B1/en not_active Expired - Fee Related
- 2004-07-22 TW TW093121879A patent/TWI327467B/en not_active IP Right Cessation
-
2005
- 2005-01-05 SG SG200500027A patent/SG113550A1/en unknown
- 2005-01-13 KR KR1020050003097A patent/KR101177782B1/en active IP Right Grant
- 2005-01-25 JP JP2005016443A patent/JP4526399B2/en not_active Expired - Fee Related
- 2005-01-26 CA CA2494489A patent/CA2494489C/en not_active Expired - Fee Related
- 2005-01-26 CN CNA2005100063270A patent/CN1669628A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP4526399B2 (en) | 2010-08-18 |
CN1669628A (en) | 2005-09-21 |
US20050161844A1 (en) | 2005-07-28 |
US7578951B2 (en) | 2009-08-25 |
TW200524574A (en) | 2005-08-01 |
KR101177782B1 (en) | 2012-08-30 |
TWI327467B (en) | 2010-07-21 |
KR20050077260A (en) | 2005-08-01 |
EP1559476A1 (en) | 2005-08-03 |
CA2494489C (en) | 2013-08-13 |
JP2005211898A (en) | 2005-08-11 |
SG113550A1 (en) | 2005-08-29 |
EP1559476B1 (en) | 2016-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2494489C (en) | Method of making microcapsules utilizing a fluid ejector | |
WO2006014256A2 (en) | System for generating a bioactive dosage form | |
KR100348935B1 (en) | Apparatus and method for producing solid form with controlled release of active ingredient | |
JP4808970B2 (en) | Spray drying system | |
CA2409093C (en) | High mass throughput particle generation using multiple nozzle spraying | |
US20070275080A1 (en) | Polymer-Based Microstructures | |
EP2654934B1 (en) | Apparatus and method for preparing an emulsion | |
US20020160109A1 (en) | Microencapsulation of drugs by solvent exchange | |
JP2003520079A (en) | Method and apparatus for aerosolizing substances | |
AU2001261625A1 (en) | High mass throughput particle generation using multiple nozzle spraying | |
US7914714B2 (en) | Methods and apparatus using electrostatic atomization to form liquid vesicles | |
WO2002009669A2 (en) | Apparatus and process to produce particles having a narrow size distribution and particles made thereby | |
JP4029252B2 (en) | Microcapsule manufacturing method and display device manufacturing method | |
KR20040036637A (en) | Pharmaceutical dosage form and method of making | |
WO2005061095A9 (en) | Process for producing microsphere and apparatus for producing the same | |
JPWO2006004069A1 (en) | Microcapsule and method for producing the same | |
JP2004035446A (en) | Method for producing microsphere and apparatus for producing the same | |
CN1777452A (en) | Apparatus and methods for repetitive microjet drug delivery | |
JP2000005593A (en) | Microcapsule encapsulating aqueous liquid and its production | |
CN107595810B (en) | Micro-nano embedded particle based on piezoelectric droplet jetting and preparation method thereof | |
CN1449764A (en) | Roxithromycin slow-released pharmaceutics and preparation process thereof | |
CN1826229A (en) | Dot-topography control of dissolution rate of bioactive agents | |
JPH08217696A (en) | Spherical nucleus for spherical granule, spherical granule and their production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180126 |